Resalis Therapeutics

Executive Summary

Resalis Therapeutics, founded in 2019 and headquartered in Milan, Italy, is an innovative biotech company pioneering RNA-based therapies to address the root causes of complex metabolic disorders. The company focuses on targeting non-coding RNAs, a novel approach that aims to modulate disease pathways at the genetic level. Its lead candidate, RES-010, is designed to induce sustained weight loss and improve metabolic health, representing a potential breakthrough in obesity and metabolic syndrome treatment. Currently in Phase 1 clinical development, RES-010 leverages a proprietary RNA platform to achieve durable efficacy. Resalis's approach differentiates from traditional GLP-1 agonists by targeting upstream regulators of metabolism, offering the possibility of less frequent dosing and enhanced tolerability. With obesity prevalence rising globally, the company addresses a large and growing market. Near-term milestones include Phase 1 data readouts and potential strategic partnerships. Resalis's pre-revenue status and early clinical stage pose risks, but the novel mechanism and unmet need provide significant upside if clinical data are positive.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Data Readout for RES-01040% success
• TBDStrategic Partnership or Licensing Deal30% success
• Q2 2027IND Filing for Second RNA-Based Candidate35% success